dc.creatorFelice, Juan Ignacio
dc.creatorSchurman, León
dc.creatorMcCarthy, Antonio Desmond
dc.creatorSedlinsky, Claudia
dc.creatorAguirre, José Ignacio
dc.creatorCortizo, Ana María
dc.date.accessioned2018-06-26T17:21:36Z
dc.date.accessioned2018-11-06T11:07:41Z
dc.date.available2018-06-26T17:21:36Z
dc.date.available2018-11-06T11:07:41Z
dc.date.created2018-06-26T17:21:36Z
dc.date.issued2017-04
dc.identifierFelice, Juan Ignacio; Schurman, León; McCarthy, Antonio Desmond; Sedlinsky, Claudia; Aguirre, José Ignacio; et al.; Effects of fructose-induced metabolic syndrome on rat skeletal cells and tissue, and their responses to metformin treatment; Elsevier Ireland; Diabetes Research and Clinical Practice; 126; 4-2017; 202-213
dc.identifier0168-8227
dc.identifierhttp://hdl.handle.net/11336/50099
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1846232
dc.description.abstractAims Deleterious effects of metabolic syndrome (MS) on bone are still controversial. In this study we evaluated the effects of a fructose-induced MS, and/or an oral treatment with metformin on the osteogenic potential of bone marrow mesenchymal stromal cells (MSC), as well as on bone formation and architecture. Methods 32 male 8 week-old Wistar rats were assigned to four groups: control (C), control plus oral metformin (CM), rats receiving 10% fructose in drinking water (FRD), and FRD plus metformin (FRDM). Samples were collected to measure blood parameters, and to perform pQCT analysis and static and dynamic histomorphometry. MSC were isolated to determine their osteogenic potential. Results Metformin improved blood parameters in FRDM rats. pQCT and static and dynamic histomorphometry showed no significant differences in trabecular and cortical bone parameters among groups. FRD reduced TRAP expression and osteocyte density in trabecular bone and metformin only normalized osteocyte density. FRD decreased the osteogenic potential of MSC and metformin administration could revert some of these parameters. Conclusions FRD-induced MS shows reduction in MSC osteogenic potential, in osteocyte density and in TRAP activity. Oral metformin treatment was able to prevent trabecular osteocyte loss and the reduction in extracellular mineralization induced by FRD-induced MS.
dc.languageeng
dc.publisherElsevier Ireland
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.diabres.2017.02.011
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0168822716304752
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectBONE ARCHITECTURE
dc.subjectFRUCTOSE
dc.subjectMETABOLIC SYNDROME
dc.subjectMETFORMIN
dc.subjectOSTEOBLASTS
dc.titleEffects of fructose-induced metabolic syndrome on rat skeletal cells and tissue, and their responses to metformin treatment
dc.typeArtículos de revistas
dc.typeArtículos de revistas
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución